Effect of bradykinin on renal mesangial cell proliferation and extracellular matrix secretion

Genetics and Molecular Research

Volumn 13, Issue 1, 2014, Pages 490-498

  Liu, C Y ^a   Zhou, L L ^a   Cheng, Q ^a   Jiang, S N ^a   Sheng, J ^a   Sun, J D ^a   Zhao, J Y ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bradykinin; Extracellular signal regulated kinase; Mesangial cells; Platelet derived growth factor

Indexed keywords

ANIMALS; BRADYKININ; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR MATRIX; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN TYROSINE PHOSPHATASES; RATS;

EID: 84893973059     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.January.21.18     Document Type: Article

References (20)

1. Abadir PM, Periasamy A, Carey RM and Siragy HM (2006). Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48: 316-322.
2. Alric C, Pecher C, Schanstra JP, Bascands JL, et al. (2000). Bradykinin-induced inhibition of cell proliferation and tyrosine kinase activity in rat mesangial cells. Int. J. Mol. Med. 5: 85-93.
3. Bascands JL, Pecher C, Rouaud S, Emond C, et al. (1993). Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am. J. Physiol. 264: F548-F556.
4. Blaes N, Pecher C, Mehrenberger M, Cellier E, et al. (2012). Bradykinin inhibits high glucose-and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. Am. J. Physiol. Renal Physiol. 303: F293-F303.
5. Costa-Neto CM, Dillenburg-Pilla P, Heinrich TA, Parreiras-E-Silva LT, et al. (2008). Participation of kallikrein-kinin system in different pathologies. Int. Immunopharmacol. 8: 135-142.
6. Duka A, Duka I, Gao G, Shenouda S, et al. (2006). Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am. J. Physiol. Endocrinol. Metab. 291: E268-E274.
7. Kakoki M, Takahashi N, Jennette JC and Smithies O (2004). Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl. Acad. Sci. U. S. A. 101: 13302-13305.
8. Marceau F and Regoli D (2004). Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 3: 845-852.
9. Murakami H, Yayama K, Chao L and Chao J (1998). Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 53: 1305-1313.
10. Pawluczyk IZ, Patel SR and Harris KP (2006). Pharmacological enhancement of the kallikrein-kinin system promotes anti-fibrotic responses in human mesangial cells. Cell Physiol. Biochem. 18: 327-336.
11. Pawluczyk IZ, Tan EK, Lodwick D and Harris K (2008). Kallikrein gene 'knock-down' by small interfering RNA transfection induces a profibrotic phenotype in rat mesangial cells. J. Hypertens. 26: 93-101.
12. Phipps JA, Jobling AI, Greferath U, Fletcher EL, et al. (2012). Alternative pathways in the development of diabetic retinopathy: the renin-angiotensin and kallikrein-kinin systems. Clin. Exp. Optom. 95: 282-289.
13. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, et al. (2002). In vivo bradykinin B2 receptor activation reduces renal fibrosis. J. Clin. Invest. 110: 371-379.
14. Tan Y, Hutchison FN and Jaffa AA (2004). Mechanisms of angiotensin II-induced expression of B2 kinin receptors. Am. J. Physiol. Heart Circ. Physiol. 286: H926-H932.
15. Tan Y, Wang B, Keum JS and Jaffa AA (2005). Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am. J. Physiol. Renal Physiol. 288: F483-F492.
16. Tan Y, Keum JS, Wang B, McHenry MB, et al. (2007). Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 293: F1026-F1035.
17. Tang SC, Leung JC and Lai KN (2011). The kallikrein-kinin system. Contrib. Nephrol. 170: 145-155.
18. Tomita H, Sanford RB, Smithies O and Kakoki M (2012). The kallikrein-kinin system in diabetic nephropathy. Kidney Int. 81: 733-744.
19. Wright JK, Botha JH and Naidoo S (2008). Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. Tumour Biol. 29: 130-136.
20. Zhang JJ, Bledsoe G, Kato K, Chao L, et al. (2004). Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 66: 722-732.